medigraphic.com
ISSN 1561-3011 (Digital)

2012, Número 2

<< Anterior Siguiente >>

Rev Cubana Invest Bioméd 2012; 31 (2)


Taquicardia ventricular polimórfica catecolaminérgica

Cruz CM

Idioma: Español
Referencias bibliográficas: 44
Paginas: 187-198
Archivo PDF: 135.35 Kb.


RESUMEN

La taquicardia ventricular polimórfica catecolaminérgica es una canalopatía caracterizada por la inducción de arritmias ventriculares polimórficas en presencia de catecolaminas. Deberá sospecharse en todo paciente joven, en especial niño o adolescente, que presente síncopes relacionados con el ejercicio físico o el estrés emocional, que no tenga cardiopatía estructural y que su electrocardiograma muestre un intervalo QT normal. Es poco frecuente, pero importante por el riesgo elevado de muerte súbita, que en ocasiones puede ser el debut. Las arritmias ventriculares son polimórficas o bidireccionales, fácilmente inducibles con el ejercicio físico y con infusión de isuprel, tienen un umbral predecible y una complejidad progresiva. Los antecedentes patológicos familiares de muerte súbita se observan entre el 30 y 40 % de los pacientes. Se han identificado 2 mutaciones genéticas causantes de la entidad (receptores de rianodina 2, con herencia autosómica dominante y calsecuestrina 2, con herencia autosómica reseciva); pero solo entre 50-55 % de los enfermos se ha testado una mutación causal. Las mutaciones condicionan la fuga de Ca2+ del retículo sarcoplásmico que favorece el origen de posdespolarizaciones tardías, las que inducirán la actividad ectópica ventricular. Los â-bloqueadores son el tratamiento de elección. El desfibrilador automático implantable está indicado en los pacientes recuperados de un evento de muerte súbita y en los sintomáticos a pesar del tratamiento farmacológico. La denervación simpática cardíaca izquierda, el verapamilo, la flecainida y la propafenona, son opciones alternativas en los sintomáticos a pesar del uso de β-bloqueadores.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Marks A, Priori S, Memmi M, Kontula K, Laitinen PJ. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia J Cell Physiol. 2002;190:1-6.

  2. Reid DS, Tynan M, Braidwood L, Fitzgerald. Bidirectional tachycardia in a child. A study using His bundle electrography. Br Heart J. 1975;37:339-44.

  3. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: Report of four cases. Br Heart J. 1978;40(Suppl):28-37.

  4. Dubner SJ, Gimeno GM, Elencwajg B et al. Ventricular fibrillation with spontaneous reversion on ambulatory ECG in the absence of heart disease. Am Heart J. 1983;105:691-3.

  5. Cohen TJ, Liem LB, Hancock EW. Association of bidirectional ventricular tachycardia with familial sudden death syndrome. Ain J Cardiol. 1989;64:1078- 9.

  6. De Paola AAV, Horowitz LN, Marques FB. Control of multiform ventricular tachycardia by propranolol in a child with no identifiable cardiac disease and sudden death. Am Heart J. 1990;119:1429-32.

  7. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512-9.

  8. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).Circulation. 2002;106:69-74.

  9. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200.

  10. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378-84.

  11. Leite LR, Ponzi Pereira KR, Alessi SR, de Paola AAV. Catecholaminergic polymorphic ventricular tachycardia. An important diagnosis in children with syncope and normal heart. Arq Bras Cardiol. 2001;76:63-74.

  12. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4(5):675-78.

  13. Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol. 1999;34:201522.

  14. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42:863-70.

  15. Aizawa Y, Komura S, Okada S, Chinushi M, Aizawa Y, Morita H, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Int Heart J. 2006;47:3819.

  16. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001;103:48590.

  17. Jiang D, Wang R, Xiao B, Wang R, Choi P, Zhang L, et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005;97:117381.

  18. George CH, Jundi H, Walters N, Thomas NL, West RR, Lai FA. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res. 2006;98:8897.

  19. George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003;93:53140.

  20. Liu N, Rizzi N, Boveri L. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learn from genetic diseases and transgenic mice? J Mol Cell Cardiol. 2009;46:149-59.

  21. Di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2006;114:10129.

  22. Viatchenko-Karpinski S, Terentyev D, Gyorke I, Terentyeva R, Volpe P, Priori SG, et al. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ Res. 2004;94: 471-7.

  23. Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC. et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm. 2006;3:800-5.

  24. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. 2004;109:3208-14.

  25. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res. 2005;96:e7782.

  26. Nam GB, Burashnikov B, Antzclevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation. 2005;11:2727-33.

  27. Schwensen C. Ventricular tachycardia as the result of the administration of digitalis. Heart. 1922;9:199-204.

  28. Stubbs WA. Bidirectional ventricular tachycardia in familial hypokalaemic periodic paralysis. Proc R Soc Med. 1976;69:2234.

  29. Morita H, Zipes DP, Morita ST, Wu J. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res. 2007;75:510-8.

  30. Berte B, Eyskens B, Meyfroidt G, Willems R. Bidirectional ventricular tachycardia in fulminant myocarditis. Europace. 2008;10:7678.

  31. Rosenbaum MB, Elizari MV, Lazzari JO. The mechanism of bidirectional tachycardia. Am Heart J. 1969;78:2-4.

  32. Baher AA, Uy M, Xie F. Bidirectional ventricular tachycardia: Ping pong in the HisPurkinje system. Heart Rhythm. 2011;8:599-605.

  33. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66-70.

  34. Priori S, Schwartz PJ, Napolitano C. Risk Stratification in the Long-QT Síndrome. N Engl J Med. 2003;348:1866-74.

  35. Zhang L, Benson D.W, Tristani-Firouzi M. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-Uwave patterns predict the KCNJ2 genotype. Circulation. 2005;111:2720-6.

  36. Hayashi M, Denjoy I, Extramiana F. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-34.

  37. Fisher JD, Krikler D, Hallidie-Smith KA. Familial polymorphic ventricular arrhythmias. A quarter century of successful medical treatment based on serial exercisepharmacologic testing. J Am Coll Cardiol. 1999;34:2015-22.

  38. Heidbuchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil. 2006;13:676-86.

  39. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eurospace. 2006;8:746-837.

  40. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358:2024-9.

  41. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:1626.

  42. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, et al. Calcium channel blockers and beta blockers versus betablockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149-54.

  43. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:3803.

  44. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology. 2011;4:128-35.




2020     |     www.medigraphic.com